Biodesix (BDSX) Common Equity (2019 - 2026)

Biodesix (BDSX) has reported Common Equity for 8 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $9.1 million, down 17.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (down 17.43% YoY), and the FY2025 annual result was -$2.5 million, down 111.81% from the prior year.
• Common Equity was $9.1 million for Q1 2026 at Biodesix, up from -$2.5 million in the prior quarter.
• Over five years, Common Equity peaked at $36.3 million in Q2 2024 and troughed at -$7.0 million in Q2 2023.
• Average Common Equity over 5 years is $7.7 million, with a median of $4.6 million recorded in 2023.
• The widest YoY moves for Common Equity: up 2026.49% in 2024, down 220.92% in 2024.
• Over 5 years, Common Equity stood at $20.6 million in 2022, then plunged by 77.77% to $4.6 million in 2023, then soared by 355.81% to $20.9 million in 2024, then slumped by 111.81% to -$2.5 million in 2025, then soared by 470.47% to $9.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $9.1 million in Q1 2026, -$2.5 million in Q4 2025, and -$1.7 million in Q3 2025.